NexgenRx: Top 10 Undervalued Healthcare Plans Industry Stocks (NXG)
NexgenRx is now ranked among the top 10 undervalued stocks in the Healthcare Plans industry on the Toronto Stock Exchange or TSX Venture Exchange.
- A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company
- Valuation methodology provided by Stockcalc (see below)
Healthcare Plans: Companies that offer a wide variety of managed health products and services, including HMOs, PPOs, and other health insurance plans, and are largely U.S.-domiciled.
Stocks in this category are held primarily for capital appreciation.
| Symbol | Name | Close Price ($) | Valuation ($) | Difference | Average Vol (30D) | Market Cap ($M) | Yield (%) | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
| NXG | NexgenRx | 0.29 | 0.34 | 0.04 (13.8%) | 3886 | 20.9 | 3.4 | 0.0 |
All data provided as of November 12, 2024.
The list is sorted by stocks with the greatest percentage difference between valuation and price.
NexgenRx
NexgenRx Inc administers, adjudicates and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and provides ancillary services. Some of the products and services of the company are Dental Claims, Prescription Drug Claims and many more.
NexgenRx is listed under NXG on the TSX Venture Exchange.
Stockcalc
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs.
Stockcalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. Stockcalc’s Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including:
- Discounted Cash Flow (DCF)
- Price & Other Comparables
- Multiples
- Adjusted Book Value (ABV)
- Analyst Consensus
Artificial Intelligence at Report on Business
Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
